The patient benefited from a combined treatment of siltuximab, an IL-6 inhibitor, and prednisone, suggesting that targeting IL-6 with therapies like siltuximab could effectively manage severe infections in patients with DOCK8 deficiency [119]. Here, IL6 is linked to infection.